GSK Plc
Research GSK Plc (GSK) on Bullrun: valuation model: 35.4% undervalued, market cap USD 105.93B, P/E 13.8, dividend yield 3.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGSK
- ExchangeNYSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal35.4% undervalued
- Market capUSD 105.93B
- P/E13.8
- Dividend yield3.4%
- Financial periodQ1 2026
- RevenueUSD 7.63B
- Net incomeUSD 1.74B
- Free cash flowUSD 698.00M
- Gross margin75.4%
Valuation Snapshot
Bullrun's latest valuation model marks GSK Plc as 35.4% undervalued; latest market cap is USD 105.93B; P/E is 13.8; dividend yield is 3.4%.
About GSK Plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Frequently asked questions
Is GSK Plc overvalued or undervalued?
Bullrun's valuation model currently marks GSK Plc as 35.4% undervalued.
What is GSK Plc's market cap?
GSK Plc's market capitalization is USD 105.93B.
What is GSK Plc's P/E ratio?
GSK Plc's price-to-earnings (P/E) ratio is 13.8.
Does GSK Plc pay a dividend?
GSK Plc has a dividend yield of 3.4%.
What does GSK Plc do?
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.